Everything below concerns Tesamorelin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Size of wound: Should be accurately measured at time of initial presentation and regularly remeasured until wound resolution. Wound location: Very useful consideration in many chronic wounds, such as diabetic foot ulcers, pressure ulcers, and venous ulcers. Acute wounds will be located in areas consistent with the mechanism of injury (e.g. diagonal chest wall bruising from seatbelt following car accident). Wound bed: A healthy wound bed will appear pink due to healthy granulation tissue. Presence of a dark red wound bed which bleeds easily on contact or excess granulation tissue (i.e. hypergranulation tissue) may indicate the presence of an infection or non-healing wound. Wound depth: The depth of a wound is often not apparent on visual inspection alone. Proper evaluation of wound depth includes use of a probe to measure wound depth and evaluate for undermining of wound edges or sinus/fistula formation. Necrotic tissue, slough, eschar: Wounds may be covered with a layer of dead tissue which may appear cream/yellow in color (slough) or as a black, hardened tissue (eschar). Removing this tissue is critical for properly evaluating both the depth of a wound and quality of the wound bed, and promotes wound healing. Wound edges: May provide clues to cause of specific wounds, such as gently sloping edges of venous ulcers or rolled edges of certain tumors.
Prestium Pharma: Luxiq (betamethasone valerate) Foam, 0.12% is a mid-strength corticosteroid foam used primarily to treat psoriasis or other inflammatory conditions of the scalp. Merck: Lotrisone (containing betamethasone dipropionate, clotrimazole) contains both a corticosteroid (betamethasone) and anti-fungal agent (clotrimazole) and is used to treat fungal infections that are also inflamed Leo Pharma: Taclonex (containing betamethasone dipropionate, calcipotriol) is a combination of corticosteroid (betamethasone) and a vitamin D analogue (calcipotriene) and is used to treat frequent and persistent dermatatoses by reducing inflammation and promoting healing of the skin barrier.
David Russell, consumer advocate, chief executive of Consumer NZ (1990–2007) (born 1942). 30 September – Nigel Latta, clinical psychologist and television host (Beyond the Darklands, The Politically Incorrect Parenting Show, Nigel Latta Blows Stuff Up) (born 1967).
Long before the born secret issues associated with the restricted data provisions of the US Atomic Energy Act of 1946, the US Invention Secrecy Act of 1951, and the US Patent and Trademark Law Amendments Act of 1980 and/or the increasing concerns with respect to the on-going biopiracy of natural products, and in the early 20th-century atmosphere of cultural change — not only in the proliferation of vocational universities, rather than research universities, but also in the gradual move from the disciplinary concentration on "pure science" and, perhaps, aspects of "applied science", to that of fostering "industrial science" in both primary and secondary industries — the ethical question of whether or not those universities devoted to "pure science" (viz., the discovery/creation, distillation, refinement, diffusion, and the free dissemination of knowledge for the benefit of the public) should have any interest in "applied science", and further, whether they should have any commercial interest in the products of their research and, in particular, whether they should seek patents for their discoveries. In his 1926 Presidential address to the Society of American Bacteriologists (HZ.1), Hans Zinsser spoke against "the growing tendency on the part of medical scientific workers, and bacteriologists especially, to patent discoveries of practical therapeutic and public health value" (p.157).
Sources: en.wikipedia.org
== Research == Oral administration of LGD-4033 to cynomolgus monkeys at daily doses varying from 0 to 75 mg/kg over 13 weeks demonstrated significant body weight gain in both males and females. After 48 days, the 75 mg/kg dose testing was halted due to toxicity concerns, but this did not negatively impact development of the drug as this dose is significantly higher than the doses being utilized in a phase 2 clinical trial. Two phase 1 clinical trials of LGD-4033 have been conducted and reported. The first was a single-dose study published as a conference abstract in 2010 and the second was a multi-dose study published as a journal article in 2013. The multi-dose phase 1 trial published in 2013 reported that LGD-4033 dose-dependently improved lean body mass and muscle strength in 76 healthy young men over 21 days. It was generally well-tolerated in this study, with no significant adverse effects reported. A phase 2 clinical trial, initiated on 3 November 2016, consisted of 108 women and men recovering from hip fracture surgery. The randomized study participants received either placebo or varying doses of LGD-4033 over a period of 12 weeks, with improved lean body mass as the primary endpoint. Other endpoints included satisfactory results in terms of quality of life, safety, and pharmacokinetics. This study was completed and results reported in 2017 and 2018. In the trial, LGD-4033 dose-dependently improved lean body mass and muscle strength and was reported to be safe and well-tolerated.
==== Musculoskeletal and bone tissues ==== Musculoskeletal applications represent a commercially mature sector of tissue engineering, focusing on the repair of critical-sized bone defects, articular cartilage lesions, and volumetric muscle loss. For orthopedic bone regeneration, therapeutic approaches utilize osteoconductive and osteoinductive scaffolds composed of bioceramics (such as hydroxyapatite and beta-tricalcium phosphate), biodegradable polymers, or composite hydrogels. These matrices serve as physical frameworks that recruit endogenous mesenchymal stem cells (MSCs) and promote osteogenesis. A critical challenge in bone tissue engineering is achieving adequate neovascularization within the core of large scaffolds to prevent core necrosis before host capillary ingrowth occurs. Consequently, modern biomaterial designs often implement multi-scale porosity, integrating smaller voids for nutrient diffusion with macro-channels greater than 100 micrometers, to facilitate deep cellular infiltration, matrix mineralization, and functional host tissue integration.
MIKES, Centre for Metrology and Accreditation, Finland, a research organisation Mikes (restaurant), a Canadian restaurant chain Mikes (surname), a surname Mikes, the Hungarian name for Miceşti village, Tureni Commune, Cluj County, Romania Mass-analyzed ion-kinetic-energy spectrometry in mass spectrometry
"Biosafety in Microbiological and Biomedical Laboratories", official CDC guide. "Prevention of Biological Hazards", EU-OSHA "Symbol Making", an account of the development of the symbol in 1966. "BioSeal Systems", Biosafety level 4 containment. Biohazard Remediation Compliance Overview "Example of Reclassified Biohazard to Level 4", article from The Lancet concerning the reclassification of Ebola after observation. "Biological hazards related to working alone safety", an article focusing on working alone safety when dealing with biological hazards
Ca2+ + 2 HCO−3 → CaCO3↓ + CO2 + H2O At seawater pH, most of the dissolved CO2 is immediately converted back into HCO−3. The reaction results in a net transport of one molecule of CO2 from the ocean/atmosphere into the lithosphere. The result is that each Ca2+ ion released by chemical weathering ultimately removes one CO2 molecule from the surficial system (atmosphere, ocean, soil and living organisms), storing it in carbonate rocks where it is likely to stay for hundreds of millions of years. The weathering of calcium from rocks thus scrubs CO2 from the ocean and air, exerting a strong long-term effect on climate.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.